Reimbursement of innovative pharmaceuticals in English and Spanish hospitals-The example of isavuconazole. by Jeck, Julia et al.
Mycoses. 2021;00:1–10.  wileyonlinelibrary.com/journal/myc | 1
Received: 28 April 2021  | Revised: 4 June 2021  | Accepted: 7 June 2021
DOI: 10.1111/myc.13336  
O R I G I N A L  A R T I C L E
Reimbursement of innovative pharmaceuticals in English and 
Spanish hospitals— The example of isavuconazole
Julia Jeck1  |   Sebastian M. Wingen- Heimann1,2,3  |   Christian Thielscher3 |   
Anna Kron1,2,4,5 |   Jennifer Bonn1 |   Florian Jakobs1,2,4 |   Santiago Grau6 |    
David A. Enoch7 |   Christianne Micallef8 |   Oliver A. Cornely2,5,9,10,11  |   
Florian Kron1,2,3,5
1VITIS Healthcare Group, Cologne, Germany
2Department I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany
3FOM University of Applied Sciences, Essen, Germany
4Network Genomic Medicine, University Hospital Cologne, Cologne, Germany
5Faculty of Medicine and University Hospital Cologne, Center for Integrated Oncology (CIO ABCD), University of Cologne, Cologne, Germany
6Pharmacy Department, Hospital del Mar, Universitat Autònoma de Barcelona, Barcelona, Spain
7Clinical Microbiology & Public Health Laboratory, National Infection Service, Public Health England, Addenbrookes Hospital, Cambridge, UK
8Pharmacy & Microbiology Departments, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
9Faculty of Medicine and University Hospital Cologne, Clinical Trials Centre Cologne (ZKS Köln), University of Cologne, Cologne, Germany
10Faculty of Medicine and University Hospital Cologne, Cologne Excellence Cluster on Cellular Stress Responses in Aging- Associated Diseases (CECAD), 
University of Cologne, Cologne, Germany
11Faculty of Medicine and University Hospital Cologne, Excellence Center for Medical Mycology (ECMM), University of Cologne, Cologne, Germany
Correspondence
Florian Kron, FOM University of Applied 






Background: Kron et al (Mycoses, 64, 2021, 86) found cost savings for the use of 
the innovative pharmaceutical isavuconazole in the inpatient setting in Germany 
(Bismarck- based healthcare system). Little is known about the reimbursement of inno-
vative pharmaceuticals in the inpatient setting of Beveridge- based healthcare systems.
Objectives: The aim of this study was to evaluate the market access process and re-
imbursement of isavuconazole, exemplary for innovative pharmaceuticals, in England 
and Spain.
Patients/Methods: Market access processes of both countries were described. Focussing 
on typical patient clusters for isavuconazole treatment, reimbursement data regarding 
inpatients with (i) allogeneic haematopoietic stem cell transplantation or (ii) acute myeloid 
leukaemia was considered. Data were publicly available and of high topicality (England 
2020/2021, Spain 2018). Discounting and a currency conversion to Euro were applied.
Results: This study showed that market access processes of both countries are broadly 
similar. Further, full reimbursement of isavuconazole as an innovative pharmaceutical may 
lead to reduction in resource utilisation. Without medication costs, isavuconazole can 
thus result in cost savings for both patient clusters due to a reduction in length of stay.
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in 
any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
© 2021 The Authors. Mycoses published by Wiley-VCH GmbH.
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1  |  INTRODUC TION
Critically ill or immunocompromised patients are especially prone 
to suffer from opportunistic invasive fungal diseases (IFD), such as 
invasive aspergillosis (IA) or invasive mucormycosis (IM).1,2 Recently 
published studies reported rising incidences worldwide for both 
pathogens.3,4 Moreover, the severity of IFD is reflected in its high 
mortality rates, potentially exceeding 80% in IA and 90% in IM— 
depending on the primary underlying disease, further risk factors 
and treatment.5,6
Considering the fatal outcomes of IFD, a high scope of unmet 
patients’ needs and the urgency to implement innovative anti-
fungal treatment options are required. From the European per-
spective, market access of innovative pharmaceuticals is based on 
approval by the European Medicines Agency (EMA). Since 1 January 
2021, the Medicines and Healthcare products Regulatory Agency 
(MHRA) regulates and approves medicines and medical devices in 
the United Kingdom (UK). Besides clinical safety and efficacy, the 
cost- effectiveness of an innovative product is increasingly relevant 
for the integration into clinical practice. Moreover, an adequate 
and cost- covering reimbursement for hospitals contributes to stan-
dardised application in patient care.
The reimbursement of services and pharmaceuticals relies highly 
on the structural orientation of the underlying healthcare system. 
Generally, healthcare systems are distinguishable in Bismarck or 
Beveridge- based1 or hybrid forms derived from one of both. 
Focussing on the systems’ financing, Bismarck- based healthcare sys-
tems are traditionally decentralised and funded through (mainly) so-
cial insurance contributions. In comparison, Beveridge- based 
healthcare systems are centrally structured, being (mainly) funded 
through general taxation.7 Most comparisons of healthcare systems 
in the international contexts are focussed on health care spending 
on capita or gross domestic product (GDP) benchmarking by consid-
ering healthcare- related (direct) costs.8 The study at hand, however, 
compared healthcare systems regarding their reimbursement and 
remuneration processes.
The study was conducted based on study results by Kron et al.,9 
which analysed cost- containment and reimbursement strategies of 
isavuconazole (ISA) as an example for innovative antifungal treatment 
regimens for IA and IM in Germany.9 To reveal potential differences 
and incentives in the reimbursement of innovative products com-
pared to other countries, the primary aim of this study was to analyse 
the market access process and reimbursement of ISA in England and 
Spain. Focussing on these countries was particularly interesting as 
both are representatives of Beveridge- based healthcare systems and 
are thus structured fundamentally differently to Germany (Bismarck- 
based).10 Even though the underlying reimbursement system of all 
three countries is based on the same logic, potential system- and 
country- specific differences were to be evaluated.
2  |  PATIENTS / METHODS
We described the market access processes of England and Spain 
to demonstrate the journey of new pharmaceuticals from EMA / 
MHRA approval into clinical routine. Country- specific reimburse-
ment for both the inpatient stay and the administration of innovative 
(mostly high- cost) drugs was analysed from the hospital manage-
ment perspective.
The included patient cohort was based on immunocompromised 
inpatients who (i) underwent allogeneic haematopoietic stem cell 
transplantation (HSCT) or (ii) patients who were treated for acute 
myeloid leukaemia (AML), both populations well known for their 
high risk of developing IFD and typical patients (clusters) for ISA 
treatment.11– 14 The analyses assumed a reduction in length of stay 
(LOS) in hospital by two days for patients receiving ISA as published 
by Maertens et al.15 Results were primarily given in the respective 
national currency. However, for comparison reasons, British Pound 
Sterling (£) were converted into Euro (€). With a yearly, constant rate 
of 3%, costs were updated to 2020 values. This was necessary as the 
analysis was based on remuneration catalogues of different years.16 
Due to the interactive nature of the model and the use of robust 
real- life data, a sensitivity analysis was not performed.17
2.1  |  Identification of reimbursement 
data of England
In this analysis, English HRG (Health Resource Group) data were 
retrieved from the publicly available National Tariff Workbook  1Comparable with National Health Service.
Conclusions: Expenses for innovative pharmaceuticals may be balanced or even lead 
to cost savings due to a reduction in length of stay. The latter contributes to a greater 
patient benefit. For both healthcare system, the analyses highlighted drugs’ cost- 
effectiveness and assessing its added value into reimbursement decisions is highly 
relevant.
K E Y W O R D S
antifungal treatment, Beveridge healthcare system, invasive aspergillosis, invasive fungal 
diseases, invasive mucormycosis, isavuconazole
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2020/2021 which is published annually by NHS England and NHS 
Improvement.18 According to the specified patient cohort relevant 
for an ISA treatment, appropriate HRG codes were identified. For 
each of the identified HRG codes, the non- elective spell tariffs were 
considered due to reasons of completeness and public access. These 
tariffs represent averaged resource costs for cases lying between 
the lower and upper threshold of LOS and vary according to their 
complexity and comorbidity (CC).
To calculate the HRG reimbursement for a 45- day ISA treatment, 
the non- elective spell tariff was multiplied with the market forces 
factor (MFF). The MFF helps to relativise unavoidable cost dispar-
ities of healthcare providers from different geographic locations in 
England, that is higher salaries or more expensive land.19 In this study, 
the MFF of the Cambridge University Hospitals NHS Foundation 
Trust was used exemplarily as it reflects the approximate average 
of the MFF range from approx. 1.0 to 1.25.18,19 In case the 45- day 
ISA treatment exceeded the upper LOS threshold, reimbursement 
for outlier days was additionally calculated using the additional daily 
payments given by the National Tariff Workbook 2020/2021. For 
currency conversion, a factor of € 1.1 per £ 1 was applied.20
As all incurring costs for ISA treatment are fully reimbursed,21 
drug expenses were not included in the analysis.
2.2  |  Identification of reimbursement data of Spain
Relevant data for the cost analysis (Table 1) were retrieved from 
the latest publicly available sources for the year 2018, published by 
the Ministry of Health (Ministerio de Sanidad, Consumo y Bienestar 
Social), Certificates of Discharge of the National Health System 
Register.22 These data of interest for our patient cohort included 
information regarding the AP- GRD codes (‘All- Patient’ Grupos 
Relacionados por el Diagnóstico) of the relevant patient clusters, 
such as average length of stay (ALOS) in days, upper LOS thresh-
old (days) and the regular total reimbursement values in € for each 
AP- GRD below the upper LOS threshold. As reimbursement data for 
treatment days above the upper LOS threshold (outlier days) did not 
exist within the screened sources, we assumed the costs per poten-
tial outlier day to be the averaged costs per day based on the ALOS. 
This was relevant for the case that the 45- day ISA treatment ex-
ceeded the upper LOS threshold. As in public hospitals in Spain, the 
costs of ISA are reimbursed according to the actual consumption. 
Specific drug acquisition costs were disregarded within our analysis.
2.3  |  Ethics statement
No ethical approval was required for this study as the underlying 
data were retrieved from publicly available sources.
3  |  RESULTS
3.1  |  Costs and reimbursement in English hospitals
As shown in Figure 1, the budgets of the English healthcare sys-
tem are held by 135 regional entities called Clinical Commissioning 
Groups (CCG).23 However, approval for market access and the 
assessment of the cost- effectiveness of drugs take place at a na-
tional level for England, Wales and Scotland, respectively. Thereby, 







HRG reimbursement for 45 days 
(non- elective spell tariff x MFF)
Cost savings due to reduced 
LOS of 2 days by ISA
SA20A, SA21A, SA22A, SA23Ab  n/a No national 
price
£ 40,774 (€ 44,852) £ 1812 (€ 1993)
SA25G 75 £ 16,318 (€ 
17,950)
£ 17,971 (€ 19,768) £ 799 (€ 879)
SA25H 67 £ 11,764 (€ 
12,940)
£ 12,956 (€ 14,252) £ 576 (€ 633)
SA25J 54 £ 8438 (€ 9282) £ 9293 (€ 10,222) £ 413 (€ 454)
SA25K 47 £ 7356 (€ 8092) £ 8101 (€ 8911) £ 360 (€ 396)
SA25La  26 £ 5375 (€ 5913) £ 12,323 (€ 13,555) £ 548 (€ 602)
SA25Ma 15 £ 3357 (€ 3693) £ 10,127 (€ 11,138) £ 450 (€ 495)
Note: HRG Definitions: SA20A, Bone Marrow Transplant, Allogeneic Graft (Sibling), 19 years and over; SA21A, Bone Marrow Transplant, Allogeneic 
Graft (Volunteer Unrelated Donor), 19 years and over; SA22A, Bone Marrow Transplant, Allogeneic Graft (Cord Blood), 19 years and over; SA23A, 
Bone Marrow Transplant, Allogeneic Graft (Haplo- Identical), 19 years and over; SA25G, Acute Myeloid Leukaemia with CC Score 12+; SA25H, Acute 
Myeloid Leukaemia with CC Score 9- 11; SA25J, Acute Myeloid Leukaemia with CC Score 6- 8; SA25K, Acute Myeloid Leukaemia with CC Score 4- 5; 
SA25L, Acute Myeloid Leukaemia with CC Score 2- 3; SA25M, Acute Myeloid Leukaemia with CC Score 0- 1.
Abbreviations: CC, complexity and comorbidity; HRG, Health Resource Group; ISA, isavuconazole; LOS, length of stay; MFF, market forces factor; 
n/a, not available.
a(Non- elective spell tariff + flat rate of £ 306 (€ 336) for number of days above upper LOS threshold) × MFF.
bAssumption, based on NICE (2019), p. 168.31
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a drug's positive recommendation is based on a maximum thresh-
old of £20,000– £30,000 per quality- adjusted life year (QALY).24 
Focussing on ISA and England, the National Institute for Health Care 
Excellence (NICE) would have been responsible for evaluating the 
incremental costs per QALY to build a basis for decision- making 
regarding the drug's approval and the subsequent pricing process. 
However, a formal assessment was not conducted by NICE but by 
Weidlich et al and Floros et al.25,26
Drug prices are negotiated between the Department of Health 
and Social Care (DHSC), NHS England, the Association of the British 
Pharmaceutical Industry (ABPI) and further scheme members 
considering inter alia cost- effectiveness and by using the Voluntary 
Scheme for Branded Medicines Pricing and Access (VPAS) with the 
goal to promote access of innovations by containing national spend-
ing.27 Pharmaceutical companies can give additional discounts at a 
regional level. Specialised services including treatment of rare dis-
eases and high- cost drugs are reimbursed through block contracts 
directly managed by NHS England. Thereby, reimbursement de-
pends on historic reimbursement claims.28– 30
Considering patients with an allogeneic HSCT, four HRG codes 
(SA20A, SA21A, SA22A and SA23A, all referring to allogeneic 
bone marrow transplantation) were identified. As none of these 
F I G U R E  1  Market Access Scheme in England. The market access procedure for pharmaceuticals in England is presented. The process is 
described from official approval to reimbursement in clinical routine. ABPI, Association of the British Pharmaceutical Industry; AWMSG, All 
Wales Medicines Strategy Group; CCG, Clinical Commissioning Groups; DHSC, Department of Health and Social Care; MHRA, Medicines 
and Healthcare products Regulatory Agency; NHS, National Health Service; NICE, National Institute for Health and Care Excellence; SMC, 
Scottish Medicines Consortium; QALY, quality- adjusted life year; PPRS, Pharmaceutical Pricing Regulation Scheme; UK, United Kingdom; 
VPAS, Voluntary Scheme for Branded Medicines Pricing Access
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HRG codes were priced nationally and remuneration is not publicly 
accessible, the HRG reimbursement over 45 days was estimated 
based on existing publications.31 Thus, cost savings due to a re-
duced LOS of 2 days were £ 1812 (€ 1993) for all allogeneic HSCT 
HRG codes.
HRG codes covering patients suffering from AML were, how-
ever, priced nationally and thus enabled the calculation of the actual 
45- day HRG reimbursement. The MFF of the Oxford Health NHS 
Foundation Trust of 1.10132 was included exemplarily.18 Six HRG 
codes, namely SA25G, SA25H, SA25J, SA25K, SA25L and SA25M, 
were identified which varied according to their CC score. As the du-
ration of the 45- day ISA treatment was above the upper LOS thresh-
old for HRG codes SA25L and SA25M, a daily flat rate of £ 306 (€ 
336) was added. Cost savings due to a reduced LOS of 2 days thus 
ranged from £ 360 (€ 396) in SA25K to £ 799 (€ 879) in SA25G for 
AML HRG codes. The underlying data and cost- saving results are 
summarised in Table 1.
3.2  |  Costs and reimbursement in Spanish hospitals
Receiving approval by the EMA in October 2015, the Agencia 
Española de Medicamentos y Productos Sanitarios (AEMPS) author-
ised the use of oral and parenteral ISA for the Spanish market in 
February 2016.32,33
As displayed in Figure 2, the AEMPS as an independent insti-
tution commissions the assessment of new drugs on behalf of the 
Ministry of Health by drawing up a therapeutic positioning report 
(IPT). Thereby, AEMPS evaluates the drug's added value by consid-
ering efficacy, safety and epidemiological data. Cost- effectiveness 
analyses are currently not mandatory for this decision- making pro-
cess.34 As part of the Ministry of Health, the General Directorate 
of Basic Portfolio of Services of the National Health and Pharmacy 
System (DGCCSSNS— Dirección General de Cartera Común de 
Servicios del Sistema Nacional de Salud y Farmacia) decides whether 
the drug is suitable for funding.35 Yet, an official funding approval 
does not equal the actual reimbursement in clinical practice as 
healthcare budgets are allocated regionally. Therefore, the Comisión 
Interministerial de Precios de Medicamentos y Productos Sanitarios 
(CIPM)— consisting inter alia of members of four different ministries 
and three members from different Autonomous Communities (AC)— 
decides on public reimbursement by considering the IPT and the 
drug's budget impact.34 Findings of the value dossier are relevant 
for the negotiation about the reimbursement pricing process (for 
patented drugs) which takes place at a national level between the 
Ministry of Health and the respective pharmaceutical company.34 
Having reached an agreement (less mandatory rebate of, that is 4% 
for orphan drugs),36– 38 decision- making power is forwarded to the 
AC. On regional level, further discounts can be negotiated between 
the AC and the pharmaceutical company. Depending on regional 
regulations, different committees, such as in hospitals the Comisión 
de Farmacia y Terapéutica, may then additionally decide whether 
the drug is included in the hospital portfolio.34,39
Considering patients who underwent an allogeneic HSCT, four 
AP- GRD codes (007- 1, 007- 2, 007- 2, and 007- 4) were identified. 
Only in one AP- GRD (007- 1), the upper LOS threshold was below 
the assumed 45- day ISA treatment, meaning that the assumption for 
daily costs above the upper LOS threshold was used as described 
within the responsible methods section. The total cost savings per 
patient due to a shortened overall LOS with ISA treatment within 
this patient cluster ranges between € 1279 in 007- 1 and € 1860 in 
007- 4.
For the cluster of patients with AML, the upper LOS threshold 
of the AP- GRD with the lowest severity level (690- 1) was below the 
predefined 45- day ISA treatment. Outliers were calculated as afore-
mentioned. The total cost savings per patient due to a shortened 
overall LOS with ISA treatment within this patient cluster ranges be-
tween € 642 in 690- 2 and € 1056 in 690- 1. Results for the Spanish 
reimbursement analysis are summarised in Table 2.
3.3  |  Comparison of Spanish and English values and 
patient clusters
Our AP- GRD and HRG data could be grouped into two clusters: 
patients treated for AML (cluster 1) and patients who underwent 
allogeneic HSCT (cluster 2). Figure 3 opposes both clusters for 
England and Spain. It shows that the mean reimbursement for allo-
geneic HSCT cases was higher than for AML cases. In cluster 1, both 
the mean reimbursement and the mean cost savings were greater 
in Spanish hospitals; however, the opposite was true for cluster 2. 
Further, while in cluster 1 the mean reimbursement of England ac-
counted for approximately 64% compared to the Spanish values, in 
cluster 2 the mean reimbursement of Spanish hospitals accounted 
for approximately 74% compared to England. As a reduced LOS of 
2 days was assumed for both clusters, the mean cost savings are 
proportionally stable.
4  |  DISCUSSION
To our knowledge, this is the first health- economic analysis focus-
sing on reimbursement and market access mechanisms of ISA in 
different (English and Spanish) healthcare systems. Potential dif-
ferences regarding access of innovative products between England 
and Spain (Beveridge- based healthcare systems), and Germany 
(Bismarck- based healthcare system) were to be evaluated.
Both market access processes showed similarities in their over-
all structure. While the funding process takes place at a national 
level, the reimbursement process happens mainly in the respective 
regions as healthcare budgets are allocated accordingly. Yet, differ-
ences could be seen in the negotiation during price- setting and in 
the translation into clinical routine.
Cost savings for the administration of ISA in the inpatient set-
ting were found for patients with an allogeneic HSCT and AML 
across all analysed codes in Spain and England (AP- GRD and HRG, 
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respectively). By comparing the analysis at hand with the study by 
Kron et al.,9 it could be confirmed that the administration of ISA for 
the defined patient cohort leads to cost savings in England and Spain 
as well, due to a full reimbursement and despite a different struc-
tural orientation of the underlying healthcare system.9
For both Beveridge representatives, approved innovative prod-
ucts such as ISA were fully reimbursed. The administration of ISA in 
Spanish and English hospitals was cost covering (oral and parenteral) 
and the application of ISA did not lead towards financial risks for hos-
pitals. Rather, our study results show that the use of ISA in treatment 
of IA and IM results in a reduction of resource use and, consequently, 
cost savings. ISA thus is beneficial from both a medical and a hos-
pital management perspective. Focussing on the German Bismarck 
study, Kron et al.9 described that drug costs for the administration 
F I G U R E  2  Market Access Scheme in Spain. The market access procedure for pharmaceuticals in Spain is presented. The process is 
described from official approval to reimbursement in clinical routine. AEMPS, Agencia Espanola Medicamentos y Productos Sanitarios; 
CIPM, Comision Intermisterial de Precios de Medicamentos y Productos Sanitarios; DGCCSSNS, Dirección General de Cartera Común de 
Servicios del Sistema Nacional de Salud y Farmacia; EMA, European Medicines Agency; IPT, Informe de Posicionamiento Terapeutico
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of ISA are not automatically reimbursed and cost coverage depends 
on a highly bureaucratic negotiation process.9 With regard to the 
study at hand, complex negotiations between healthcare providers 
(Germany) / Ministry of Health (Spain and England) and the phar-
maceutical companies were not country- specific but affected all 
healthcare system designs in Europe.
4.1  |  Methodological considerations
Although best practices for cost and reimbursement analyses 
were followed, this study has some limitations. Due to country- 
specific modifications of the English and the Spanish Beveridge 
system, reimbursement processes may vary during the years. 
Reimbursement processes are most often dynamic and ongoing, 
which should be also considered interpreting current study results. 
Yet, as each of the hospital (management) systems are based on 
diagnosis- related groups (DRG), the countries’ systems were – up to 
a certain extent – comparable.40
The analyses of both countries focussed on haematological diag-
noses and treatments irrespective of the CC level and did not con-
sider any other underlying diseases. However, patients with lower 
CC levels rarely occur in IA or IM. For reasons of completeness, we 
nevertheless examined all identified codes for both clusters.
In the English analysis the HRG codes SA20A, SA21A, SA22A and 
SA23A national tariffs were not publicly available as there were no 











Cost savings due to reduced 
LOS of 2 days by ISA
007- 1a  43 27 € 26,786 € 28,770 € 1279
007- 2 50 30 € 30,256 € 30,256 € 1345
007- 3 58 37 € 32,723 € 32,723 € 1454
007- 4 124 57 € 41,842 € 41,842 € 1860
690- 1a  26 11 € 8715 € 23,769 € 1056
690- 2 64 17 € 14,455 € 14,455 € 642
690- 3 77 24 € 20,844 € 20,844 € 927
690- 4 86 33 € 22,509 € 22,509 € 1000
Note: AP- GRD Definitions: 007- 1, Allogenic Bone Marrow Transplantation – level of severity 1; 007- 2, Allogenic Bone Marrow Transplantation – level 
of severity 2; 007- 3, Allogenic Bone Marrow Transplantation – level of severity 3; 007- 4, Allogenic Bone Marrow Transplantation – level of severity 
4; 690- 1, Acute Leukaemia – level of severity 1; 690- 2, Acute Leukaemia – level of severity 2; 690- 3, Acute Leukaemia – level of severity 3; 690- 4, 
Acute Leukaemia – level of severity 4.
Abbreviations: ALOS, average length of stay; AP- GRD, ‘All- Patient’ Grupos Relacionados por el Diagnóstico; ISA, isavuconazole; LOS, length of stay.
aAP- GRD reimbursement below upper LOS threshold + average reimbursement per day below upper LOS threshold for days above upper LOS 
threshold.
F I G U R E  3  Comparison of cost 
savings in the use of ISA considering 
two clusters. The two indications ‘acute 
myeloid leukaemia’ and ‘allogeneic 
HSCT’ are compared considering their 
mean cost savings in England and Spain, 
respectively. HSCT, haematopoietic stem 
cell transplantation; ISA, isavuconazole
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prices set across any setting.18 As the assumed tariff was retrieved 
from the sum of the weighted average of harvesting costs and allo-
geneic transplant costs for elective patients,31 the reimbursement of 
our calculation may have been overestimated. Yet, other data were 
not publicly accessible.
4.2  |  Further implications
For further implications, we suggest to not only analyse the reim-
bursement of innovative pharmaceuticals at a hospital level but also 
to consider the system perspective. Recently, innovative funding 
strategies are more in focus of scientific discourse, with the aim to 
make reimbursement systems more transparent and sustainable. 
These strategies aim at reforming traditional reimbursement pro-
cesses by facilitating a rapid market access and shared- cost risk 
schemes for effective, innovative products. One of these funding 
strategies is the so- called ‘value- based pricing’ (VBP) concept which 
is covered by the report of the expert panel on effective ways of 
investing in health by the European Commission.41 Within this con-
cept, value is defined as the therapeutically added value of a drug. 
VBP aims to set innovation and affordability in context with each 
other.41,42 Even though VBP may have drawbacks, such as incentiv-
ising research for high- cost drugs (against rare diseases) with a po-
tential negative impact on healthcare budgets, it also brings major 
advantages. For instance, VBP contributes to (i) an in- depth assess-
ment of cost- effectiveness focussing on patient- related outcomes41 
and thereby (ii) increases transparency while reducing current confi-
dential ‘black box’ reimbursement deals.
The English healthcare system is defined as a ‘value- based health 
care’ as it aims to have the patients’ interests in the centre of all 
processes, not only the reimbursement one. However, such a com-
prehensive system needs all affected stakeholders to pull together 
by unifying culture, language, and behaviour.43 This example shows 
that reformation of a healthcare (or reimbursement) system is a pro-
cess rather than a fast changeover.
We encourage debate to improve the development of traditional 
reimbursement systems towards more innovative approaches while 
also focussing on the alignment of processes across country borders. 
However, the concept would prevent a neglect of country- specific 
differences, that is in healthcare budgets which can exemplarily be 
seen in the health expenditures, given in shares of GDP (9.6% [UK] 
and 8.9% [Spain] in 2017).44
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